Education
About Us
Working with TipRanks
Follow Us
Neumora Therapeutics, Inc. (NMRA)
NASDAQ:NMRA
Earnings Data
Report Date
Aug 12, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.37Last Year’s EPS
-0.37Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 12, 2025
|% Change Since: 4.55%
|Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Neutral
Neumora Therapeutics reported significant advancements in their pipeline and financial strength, positioning them well for future milestones. However, challenges in clinical study enrollment and increased net losses indicate hurdles that need addressing.Company Guidance
During Neumora Therapeutics' First Quarter 2025 Financial Results Conference Call, several key metrics were provided. The company is on track to deliver top-line data for NMRA-511 in Alzheimer's disease agitation by the end of 2025. The Phase 3 KOASTAL program for navacaprant in major depressive disorder (MDD) is ongoing, with top-line data for KOASTAL-3 expected in the first quarter of 2026 and KOASTAL-2 in the second quarter of 2026. A $125 million debt facility was secured, with $20 million drawn at close, extending the cash runway into 2027. The net loss for the first quarter of 2025 was $68 million, and cash, cash equivalents, and marketable securities were $249.4 million as of March 31, 2025.Strong Financial Position
Neumora entered into a $125 million debt facility with K2 HealthVentures, with $40 million available for draw this year. This strengthens their financial position, allowing operations to extend into 2027.
Pipeline Advancements
Neumora is advancing multiple programs such as NMRA-511 and navacaprant, with significant upcoming data milestones expected in 2025 and 2026.
Intellectual Property Portfolio
Neumora's pipeline is supported by a strong intellectual property portfolio with worldwide rights and composition of matter patents extending into the 2040s.
Novel Mechanisms in Development
The company is focusing on novel mechanisms of action in neuroscience drug development, such as the kappa opioid receptor antagonist and M4 PAMs.
---
NMRA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NMRA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2025 | $0.66 | $0.69 | +4.55% |
Mar 03, 2025 | $1.56 | $1.40 | -10.26% |
Nov 12, 2024 | $13.64 | $11.31 | -17.08% |
Aug 06, 2024 | $11.96 | $11.99 | +0.25% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Neumora Therapeutics, Inc. (NMRA) report earnings?
Neumora Therapeutics, Inc. (NMRA) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
What is Neumora Therapeutics, Inc. (NMRA) earnings time?
Neumora Therapeutics, Inc. (NMRA) earnings time is at Aug 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NMRA EPS forecast?
NMRA EPS forecast for the fiscal quarter 2025 (Q2) is -0.37.
---